LovelyMeds review

LovelyMeds’ tirzepatide page lists $235 for a one-month option, with monthly equivalents of $199 over three months, $175 over six and $150 over twelve. The lowest ongoing equivalent requires the longest stated term. Confirm whether the full term is prepaid.

FDA issued warning letter 716829 to Lovely Meds, Inc. dba Lovely Meds on September 9, 2025, after reviewing lovelymeds.com in August. The agency cited marketing that it said misleadingly implied compounded semaglutide and tirzepatide were the same as FDA-approved products.

This is a dated finding about the cited marketing, not an assertion that today’s offer remains identical or that a particular patient’s medication is defective. The letter deserves consideration alongside the plan terms. This check did not establish whether FDA later accepted corrective action or issued a closeout.

The page also advertises a NEW60 discount and a $90 first-period figure tied to its lower plan rate. That does not establish a $90 standalone monthly subscription. Compare the actual initial charge, term and renewal rate before deciding that one offer is cheaper than another.

The offer concerns compounded tirzepatide with B12 in injectable multi-dose vials. Ask the clinician about the particular formulation and the pharmacy’s instructions for your prescription. Neither a vial image nor a monthly equivalent tells you how much usable medication is supplied.

Obtain the named pharmacy, cancellation deadline, refund treatment for unused supply and follow-up arrangements. Those details were not fully established by the product page. A separate semaglutide listing needs its own quote; tirzepatide’s discount ladder should not be transferred to it.